Virtus Investment Trust has filed an updated prospectus for its Virtus KAR Health Sciences Fund, marking a significant step in its commitment to investor transparency and education. This update, filed on October 28, 2026, outlines the fund's investment objectives, fees, and operational strategies, which are crucial for potential investors considering their options in the health sciences sector.

The Virtus KAR Health Sciences Fund aims for long-term capital appreciation through investments in health sciences-related companies. The fund is designed to attract investors looking for opportunities in a sector that has shown resilience and growth potential. This update reflects Virtus's ongoing efforts to provide clear and comprehensive information to its investors, which is essential for making informed decisions.

Background

Virtus Investment Trust, incorporated in Massachusetts, operates in the investment sector. The company is known for managing a variety of mutual funds and investment products aimed at delivering value to its clients. Recent filings indicate that Virtus has been active in updating its fund offerings, with multiple filings on October 28, 2026, including several 497K forms.

What the Filing Says

The filing includes a detailed summary prospectus for the Virtus KAR Health Sciences Fund, emphasizing its investment objective of seeking long-term capital appreciation. The fund invests at least 80% of its net assets in health sciences-related companies, which are believed to have sustainable competitive advantages. The prospectus also outlines the fees associated with investing in the fund, including management fees and shareholder servicing fees.

"Before you invest, you may want to review the fund’s prospectus, which contains more information about the fund and its risks," the document states.

Impact

This update may significantly affect current and potential investors in the health sciences sector, as it provides clarity on the fund's strategies and associated costs. Investors looking for exposure to health sciences will find this information valuable in assessing their investment choices. Moreover, the transparency offered by Virtus may set a standard for other firms in the investment industry, compelling them to enhance their disclosures.

What's Next

The filing does not specify what happens next, but it indicates that the fund's investment adviser has agreed to limit total operating expenses for Institutional Class Shares through October 31, 2027. This commitment may lead to further updates as the fund continues to evolve and respond to market conditions.